Instead of targeting two hormone pathways, Retatrutide activates three: GLP-1 GIP Glucagon receptors Because it targets an additional metabolic pathway, researchers are studying whether Retatrutide may influence both appetite regulation and energy expenditure
Drug Development and Industrial Pharmacy, 45(9), 14031420
DISCLAIMER : if you're concerned about your B12 levels, please speak with your healthcare provider
Key facts Kaiser California base plans exclude GLP-1 weight-loss drugs for new starts with BMI below 40 (since January 2025) a more restrictive threshold than Wegovy's FDA indication (BMI 30+), matching the Blue Shield of California restriction applied at the same time
Gastrostomy tube feeding in the remaining stomach normalises glucose levels, GLP-1, insulin and the incretin response6
Rao SS, Ozturk R, Laine L (2005)